S tudies in experimental psychology, neuroscience, and rehabilitation science explore adaptations in neural tissue with respect to type, intensity, and frequency of a stimulus. Studies of experience-dependent synaptic-plasticity in nonhuman animals 1,2 and humans 3 demonstrate that large quantities of practice lead to cortical reorganization and improved behavioral function. Similar studies link neural changes with recovery of function and learning in adults after stroke. 4,5 These data indicate that increased practice leads to greater skill, as long as practice is challenging, progressive, and skill based. 4,6 Meta-analyses 7,8 also suggest a positive doseresponse relationship.
S tudies in experimental psychology, neuroscience, and rehabilitation science explore adaptations in neural tissue with respect to type, intensity, and frequency of a stimulus. Studies of experience-dependent synaptic-plasticity in nonhuman animals 1, 2 and humans 3 demonstrate that large quantities of practice lead to cortical reorganization and improved behavioral function. Similar studies link neural changes with recovery of function and learning in adults after stroke. 4, 5 These data indicate that increased practice leads to greater skill, as long as practice is challenging, progressive, and skill based. 4, 6 Meta-analyses 7, 8 also suggest a positive doseresponse relationship.
Some define dose as the amount of time actively spent in practice 9 or the number of repetitions of a movement. 10, 11 For this article, dose is defined as total time scheduled for therapy (eg, 3 hours/d×(10 days)=30 hours). Time scheduled for therapy may not accurately reflect actual practice time or the number of movement repetitions, 12 so this measure is not ideal; however, time scheduled for therapy is the only consistently reported metric in rehabilitation research studies.
Response may be defined as improved function or reduced impairment. For this article, response was defined as a standardized effect size, Hedges' g, which shows improved function or reduced impairment on a standardized, validated behavioral test. Effect sizes reported here were based on the primary or secondary outcomes of randomized controlled trials (RCTs) found through the systematic review.
Our objective was to quantify the magnitude of functional improvement gained by increasing therapeutic time after stroke. Our meta-analysis builds on work addressing doseresponse in a binary manner: Is more therapy better than less therapy? [7] [8] [9] To meet this objective, we purposely included articles with different types of therapy interventions because it is unclear at this time how the type of therapy provided affects responses. 13, 14 By reviewing RCTs with different therapy times for treatment and control groups, we modeled the effect of increased time scheduled for therapy on standardized measures of recovery. We tested linear and quadratic effects of therapy time while controlling for linear and quadratic effects of years from the initial stroke to the beginning of the RCT. We chose this approach because it is unlikely that any effects are linear. We hypothesized that increased therapy time would positively affect outcomes, 7, 8 whereas time after stroke might negatively affect outcomes.
Study Selection
An initial 832 titles were identified. After screening titles and abstracts and removing duplicates, 138 articles were assessed (Appendix I in the online-only Data Supplement). Details of the interventions and the time scheduled for therapy in the treatment and control groups were extracted. Exclusion criteria were (1) lack of randomization with a control, (2) studied children (age, <18 years), (3) >30% participants with neurological disorders other than stroke, (4) therapy in combination with a pharmaceutical treatment or electric stimulation, (5) dosematched treatment and control conditions, and (F) unpublished or not translated into English. Thirty-seven trials remained (Table I in the online-only Data Supplement) and were included in the assessment of study quality. 13, The Physiotherapy Evidence Database Scale was used to rate methodological quality (www.pedro.org.au).
Quantitative Analysis
Mean, SD, and sample sizes for the treatment and control groups were entered into a spreadsheet. Standardized effect sizes (Hedges' g) and variances (V g ) were calculated. 53 Effect sizes were computed from the terminal difference between treatment and control or the difference in improvement between treatment and control, divided by the SD within groups. Subtraction was arranged so that effects favoring the treatment group were positive. Effect-size measures were analyzed using the metafor package 54 in R (cran.r-project.org; Table II in the onlineonly Data Supplement). A funnel plot was constructed. There were 3 studies with large effect sizes and low levels of precision. 38, 39, 51 These studies were removed, leaving 34 studies for inclusion in the quantitative analysis (Appendix II in the online-only Data Supplement).
Custom scripts (Appendix III in the online-only Data Supplement) tested a random-effects model for the overall effect of increased therapy dosage. The analysis was broken into 2 parts. Part 1 was congruent with previous analyses, 7, 8 calculating a summary effect size for groups who received more therapy when compared with groups who received less. Part 2 elaborated on this analysis using metaregression models to quantify the dose-response relationship controlling for other factors. Four studies were omitted from regression models because of missing data 19, 23, 30, 47 (see the NAs in Table II in the onlineonly Data Supplement); regression was based on 30 studies. Time after stroke (Yrs.PS) was the average years from hospital admission to the onset of the intervention. Total time scheduled for therapy was calculated for the treatment and control groups based on descriptions in the text. Regression models then used the difference between groups in total time scheduled for therapy (ΔTime).
Constraint time in constraint-induced movement therapy creates a problem for calculating ΔTime because it is not clear how time under constraint should be counted as time scheduled for therapy. To address this problem, we coded 3 different ΔTimes for constraint-induced movement therapy studies. In the MIN time calculation, 0% of constraint time counted as time scheduled for therapy. In the 50% time calculation, 50% of constraint time counted as time scheduled. In the MAX time calculation, 100% of constraint time counted as time scheduled. The results of the 50% time calculation are presented here because we assume that some, but not all, of constraint time was spent using the affected limb (details of all analyses are presented in Appendix II in the online-only Data Supplement).
Results
Comparing High Dose to Low Dose: There Is an Overall Benefit of Increased Time in Therapy Across studies, there was a benefit for treatment groups receiving more therapy, (g=0.35; 95% confidence interval, 0.26-0.45; Figure 1 ), which was significant, Z obs =7.21, 
Descriptive Statistics for the Regression Models
For the 30 studies included in the regression models, there were 1750 total participants. The median number of participants in treatment groups was n=21.5 and in control groups n=19.5. In treatment groups, time after stroke was 1.01±1.49 years (0.003, 5.14) shown as M±SD (Min, Max) . In control groups, time after stroke was 1.02±1.63 years (0.003, 5.38). The duration of therapy in treatment groups was 49.56±68.12 days (14, 365) . The duration of therapy in control groups was virtually identical, 49.60±68.10 days (14, 365) , because most studies were matched for treatment duration (Table I in the online-only Data Supplement). Matching studies on treatment duration means that differences in total therapy time result from changes in the frequency and intensity of therapy for a given duration. Time scheduled for therapy in treatment groups was 57.41±44.88 hours (4.0, 160. 
Quantifying Dose: Increased Scheduled Therapy Predicts Greater Recovery
To look at the linear effect of ΔTime, a series of models was tested. Model The linear effect of ΔTime was significant (P=0.04) and ΔTime 2 approached significance (P=0.09). The predicted effect sizes (ĝ) of models 3 and 4 are shown in Figure 3 . The nonsignificant effect of ΔTime 2 suggests that the basic effect of ΔTime is positive and for every additional 10 hours scheduled for therapy, the effect of ΔTime may become less positive. However, statistical power is an issue with this many moderators, so this effect should be interpreted with caution. 
Stroke
July 2014
Discussion
This meta-analysis agrees with previous work, 7, 8 suggesting a small overall benefit of augmented time in therapy (ie, more is better). The review of Kwakkel et al 7 found smaller benefits of therapy dose (≈0.20 for measures of activities of daily living and walking speed) than our overall g=0. 35 , which is likely because of differences in the methods for inclusion and analysis. It is difficult to compare our results directly with the review of Langhorne et al 8 because those authors measured odds ratios and weighted mean differences rather than standardized effect sizes. However, those authors also found what they described as modest effects of increased therapy. Our analysis goes further to suggest reliable doseresponse relationships between the time scheduled for therapy and improvement on clinical measures of function and impairment. In our analysis, neither the linear nor quadratic effects of time after stroke were significant. However, there was a significant positive effect of time scheduled for therapy on outcomes (model 1) even when controlling for time after stroke (model 3). Our evidence also suggests the potential for a nonlinear effect of time scheduled for therapy when controlling for the linear effect (model 4).
We interpret these results as strong evidence of a positive relationship between dose and response. We were able to see a positive dose-response relationship across studies rehabilitating different impairments and functions, using different interventions, and measuring outcomes with different tools. All of these factors are potential sources of noise that could mask the dose-response relationship. Thus, we interpret these effects as evidence that time in therapy is a robust predictor of recovery across different types of therapy. Our data imply that providers of rehabilitation services should consider multiple ways to increase therapy time, both within and outside formal sessions. Furthermore, there was no interaction between time after stroke and time scheduled for therapy. The lack of an interaction suggests that the benefit of large increases in therapy is similar across a range of poststroke times regardless of whether a client is several months or several years after stroke (poststroke times ranged from 0.003 to 5.38 years).
Importantly, there are complications to this effect. For instance, if started too early, intensive therapy may hinder the rate of recovery 20 or have no benefit over less intense therapies. 18 Also, too many hours of therapy may not be tolerable for participants, leading to dropouts. 22 These nonlinearities are important considerations for clinicians, which are not captured in the current analysis. As more data are added at different time points, these complexities in the dose-response relationship can be modeled more reliably.
Recovery after stroke is clearly a multidimensional problem, but it is reassuring to establish that time scheduled for therapy significantly predicted functional outcomes across studies. Our results also agree with experimental work in which dose was tightly controlled. [55] [56] [57] In those studies, the correlation between dose (measured in repetitions) and outcome was moderate (r=0.5-0.6). In comparison, our metaanalysis is limited using time scheduled for therapy as a predictor when ideally we could use active time in movement practice or movement repetitions. However, in the existing literature, the only consistently reported metric was time scheduled for therapy. Within our own data set, 23.5% of studies (8 of 34 RCTs) provided a more certain/more detailed measure than time scheduled for therapy. These studies specified active time in therapy (such as time spent walking) or gave descriptive statistics about how much therapy time was fulfilled by participants (which may include active time plus rests, demonstrations, instructions, etc., but is still a more detailed measure than time scheduled). Thus, we recommend future RCTs report active time or repetitions of an exercise for a more accurate representation of the dose of therapy received.
With 30 studies in the metaregression, we rapidly lost power to detect additional effects and interactions. Additional studies need to be included in the data set to test additional predictors (eg, stroke severity), higher order effects (eg, cubic effects), or interactions. Although the metadata approach is powerful, dose-response relationships are likely more complex than what we present here. Additional work can address this issue. We are currently conducting a systematic review that will result in a larger database of RCTs. These data will be analyzed with respect to terminal improvements and retention at long-term follow-up (the current analysis is limited by only studying terminal effects) for treatment and control groups, separately. This approach allows the modeling of dosage effects for studies with different durations, intensities, and frequencies of treatment in more homogeneous treatment groups. Furthermore, the current metadata and other experimental data 55-57 warrant larger experimental studies to explore dose-response effects. 
Disclosures
None.
Stroke
July 2014 ** denotes studies where the control group technically received therapy but no therapy relevant for the primary outcome, thus, therapy time is coded as "0 hrs" for analysis, or the exact time for the control group was not reported, but the difference between treatment and control was explicitly stated (viz, Hunter et al., 2011). *** denotes studies where there was no description of time scheduled for therapy. These studies were included in the overall analysis because the treatment group did receive more therapy than the control group. However, these studies were omitted from the regression analyses because no statistics on the difference in therapy time could be computed. T denotes standard deviations that were estimated from inferential statistics reported in the text.
Supplemental
**denotes studies that did not have necessary statistics for the primary outcome (e.g., nonparametric analysis), so a secondary outcome was used.
C denotes the uncertain time difference for CIMT studies. In the 50% Time analysis (shown), 50% of constraint time was counted as therapy time.
RM denotes an outlying study that was removed from the overall analysis and from the regression models. 
Qualtiy Assessment.
One author (KRL) assessed the methodological quality and risk of bias in individual studies using the PEDro scale. The different criteria of the PEDro scale were categorized according to their risk of bias: selection bias, performance bias, detection bias, and attrition bias. Criteria that did not naturally fit into one of these categories are not discussed, but the full data for each criterion are reported in Table III . In summary, PEDro scores for the various studies were moderate, with a mean of 6.65 and SD of 1.08, but the risk of specific biases are discussed below. Note. A "1" indicates that a study met that particular criterion, a "0" indicates that a study did not meet that criterion or that not enough information was given to make an assessment. C1 = Eligibility criteria were specified; C2 = Participants were randomly allocated to groups; C3 = Treatment allocation was concealed; C4 = Groups were similar at baseline; C5 = Blinding of participants; C6 = Blinding of therapists administering treatment; C7 = Blinding of assessors for outcome measures; C8 = Measurement of key outcome from >85% of participants; C9 = Intention to treat analysis; C10 = Between-groups statistical comparison is reported for key outcome; C11 = Measures of central tendency and variability are provided.
Risk of selection bias (C2, C3, and C4).
Selection bias refers to initial differences between treatment and control groups at baseline, which would then obfuscate treatment effects in the data. Risk of selection bias was relatively low across the collected studies. Random allocation was specified in 97% of studies, concealment of the treatment allocation was specified in 62% of studies, and the equivalence prognostic indicators and key outcomes was specified in 89% of studies. Thus, the majority of studies randomly allocated participants to treatment groups and this random allocation equated the groups on key outcome measures and prognostic indicators at the beginning of the trial.
Risk of performance bias (C5 and C6).
Performance bias refers to differences between groups in the type/level of care that is provided and a lack of blinding in either the participants or the therapists administering treatment. A lack of blinding increases the risk that knowledge of the intervention, beyond the intervention itself, will influence the outcome. Risk of performance bias was high in the collected studies. The blinding of participants was specified in none of the included studies and the blinding of therapists administering treatment was specified in only 5% of studies.
The extent of this risk depends on how "blinding" is considered. We used a strict definition of blinding, meaning that participants or therapists were not aware of the condition to which they were assigned. For most physical and occupational therapy protocols, blinding at this level is not feasible. For instance, in bodyweight-supported treadmill walking or in constraint induced movement therapy both the participant and the therapist administering treatment will be aware of what treatment the participant has been allocated to. Although it is not specifically reported, it might be better to ask if participants were naive to the hypotheses of the trial rather than being truly blind to their condition. Therefore, the high risk of performance bias across studies is a concern, but it is a general concern for physical and occupational therapy protocols in which the treatment being received is clear to the participant and the therapist administering the treatment. Thus, although the risk of performance bias is high in the collected studies, we do not think it is higher than the risk of performance bias in physical and occupational therapy studies in general.
Risk of detection bias (C7).
Detection bias refers to potential differences in how outcomes were measured for each group. Blinding of the outcome assessor helps reduce the risk that knowledge of the treatment allocation is affecting the outcome measurement. Successful blinding of assessors was reported in 81% of studies. While this means that assessors were successfully blinded in all but a minority of studies, it is not clear to what extent a lack of blinding could influence the results of several of the outcomes. Some outcome measures are more objective (e. g., the 6-metre walk test, gait speed on a treadmill) and probably less susceptible to bias, but other measures (e. g., the Action Research Arm Test or Fugl-Meyer Assessment) maybe more susceptible to assessor bias. This suggests the risk of detection bias was low to moderate across studies.
Risk of attrition bias (C8 and C9).
Attrition bias refers to differences in the withdrawal rates between each group that might affect the outcome of the study. Protocols were completed by >85% of the randomized participants in 86% of studies and an intention to treat analysis was specified in 54% of studies. The intention to treat criterion was granted if the study specified that all subjects received treatment according to their initial allocation even if "intention to treat" was not specifically stated in the analyses (as per PEDro guidelines). It should also be noted that none of the included studies specifically reported violating an intention to treat analysis. Thus, for studies that failed to meet this criterion, it is not clear if this is due to non-adherence or to a lack of reporting. Given the high completion rates for participants in these studies and the ambiguity regarding intention to treat analysis, we think that the risk of attrition bias was generally low across studies.
Supplemental Appendix II: Supplemental Analyses Removal of Outlying Studies
Prior to statistical analysis, we constructed a funnel plot of all of the 37 studies that were assessed for quality 36 ) had extremely positive effect sizes but low levels of precision ( Figure II) . A statistical test of asymmetry in the funnel plot was significant, t(35) = 2.49, p = 0.02, (using the regtest() function in R). Thus, these three studies were removed from subsequent analyses. Removal of these studies makes the estimated overall effect more conservative (because extreme positive values have been removed) and improves the quality of the data (because extreme values with low precision have been removed). 
Max-Time and Min-Time Calculations
As mentioned in the methods, including data from constraint induced-movement therapy studies presents a unique problem for calculating the time scheduled for therapy because it is not clear how constraint time should be counted. In the main text, we presented the results of our "50% Time" calculation. We think that this calculation is the most reasonable because it counts 50% of constraint time as therapy time and thus assumes that at least some time under constraint is spent in active movement practice. We also conducted a "Max Time" calculation, in which all of constraint time is counted as time scheduled for therapy, and a "Min Time" calculation, in which none of constraint time is counted as time scheduled for therapy. The assumptions of neither of these models are truly feasible, but they provide a useful reference point for understanding the relationship between time scheduled for therapy and magnitude of recovery. Furthermore, time scheduled for therapy is a significant predictor of recovery under two of the three calculations, suggesting that time scheduled for therapy is a relatively robust predictor of recovery.
The different values of the Min Time, 50% Time and Max Time calculations are shown in Table IV . These calculations change the difference in time scheduled for therapy (ΔTime) for constraint studies by changing the time scheduled for therapy for the treatment groups; time scheduled for therapy for the control groups is the same in all three calculations. As such, only the linear (e.g., ΔTime MAX ) and quadratic (e.g., ΔTime 2 MAX ) predictors of time scheduled for the therapy are affected in the meta-regressions. 
Meta-Regression Using the Min-Time Calculation
We constructed meta-regression models to predict a standardized measure of effectsize (g; see Figure 1 in the main text) using linear and quadratic effects of time post-stroke (see Supplemental Table II for Table V . This model showed that, when controlling for other variables, there was a no effect of time post-stroke (p = 0.60), Yrs.PS 2 (p =0.78), or ΔTime MIN (p = 0.54). Table VI . This model showed that, when controlling for other variables, there was no significant effect of time post-stroke (p = 0.93), no effect of Yrs.PS 2 (p = 0.95), no effect of ΔTime MIN (p = 0.56), and no effect of ΔTime 2 MIN (p = 0.47). Adding the interaction term did not change the significance of any of the predictors and did not substantially alter the magnitude of the slopes. Therefore, the maineffects model is presented in Table VI . 
Meta-Regression Using the Max-Time Calculation
Based on the data above we constructed meta-regression models to predict a standardized measure of effect-size (g; see Figure 1 in the main text) using linear and quadratic effects of time post-stroke (see Supplemental Table II for Table  VII . This model showed that, when controlling for other variables, there was no effect of years post-stroke (p = 0.92) and no quadratic effect of years post-stroke (p = 0.78). There was, however, a positive effect of ΔTime MAX (p = 0.05). This interaction was marginally significant (p = .06), but did not substantially alter the magnitude or direction of the other effects, so the main effects model is presented instead.
Summarizing the Different Meta-Regression Models
With three different calculations and several models for each calculation it can be difficult to see how the models tell a cohesive story. However, in looking at the various parameters across the different models and calculations, there is a generally positive effect of time scheduled for therapy. These data are summarized in Table IX, Additionally, when looking at the linear effect of time scheduled for therapy without controlling for other factors, the effect of time scheduled for therapy was positive in all three analyses (Table X) . Across these models, the effect of ΔTime ranged from 0.0079 to 0.0365. Only in the minimum time calculation was the effect of ΔTime not significant but even in that case the parameter estimate was positive (but not significantly different from zero). 
